Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
- Registration Number
- NCT02647515
- Lead Sponsor
- Ruijin Hospital
- Brief Summary
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- age≥18 years
- PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions
- NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle)
Exclusion Criteria
- intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy
- previous intravitreal injection of ranibizumab or bevacizumab in either eye
- previous intravitreal corticosteroids injection in either eye
- pregnancy or current oral contraceptive intake
- usage of clopidogrel bisulfate or coumadin
- uncontrolled hypertension and cardiac disease
- uncontrolled renal or liver disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ranibizumab ranibizumab -
- Primary Outcome Measures
Name Time Method vitreous hemorrhage 12 months intraocular pressure 12 months
- Secondary Outcome Measures
Name Time Method